EUCTR2005-000142-37-HU进行中（未招募）不适用
Efficacy and Safety of subcutaneous administration of XM01 compared to Epoetin beta in anaemic chronic renal failure patients not yet receiving dialysis and in maintenance phase treatment with Epoetin beta. A multinational, multicentre, randomised, controlled, double-blind, comparative, parallel group Phase III study.
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 255
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients of any ethnic origin meeting all criteria listed below will be included in the study:
- •1. Patients being treated for known renal anaemia, on maintenance treatment with Epoetin beta.
- •2. Aged =18 years.
- •3. Male or female.
- •4. Patients with chronic renal failure not yet receiving dialysis and having a glomerular filtration rate (GFR) < 60 mL/min/1.73 m2 within the last three months (estimated by Cockroft-Gault formula).
- •5. Patients should be on maintenance treatment with once, two or three times weekly s.c. administration of Epoetin beta for at least 3 months prior to enrolment.
- •6. Patients should be on stable therapy with Epoetin which refers to a stable haemoglobin level defined as: at least four measurements within the last eight weeks with the difference between the highest and lowest value of less than 2 g/dL. There should be at least 1 week between each of the four haemoglobin measurements.
- •7. Haemoglobin concentration = 9.5 g/dL and <12.0 g/dL within the last eight weeks (mean value of four measurements, separated from each other by at least a week).
- •8. Serum ferritin >100 µg/L or TSAT >20% (within the last four weeks prior to enrolment).
- •9. Able to understand and follow instructions and able to participate in the study for the entire period.
- •10. Signed and dated written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients presenting at Visit 1 with any of the following will not be included in the study:
- •1. Female patients of childbearing potential.
- •2. Patients with active bleeding.
- •3. Red blood cell transfusion within the last three months.
- •4. Uncontrolled severe hypertension defined as systolic blood pressure >180 mmHg and/or diastolic blood pressure >110 mmHg
- •5. History of myocardial infarction, cerebrovascular accident, percutaneous transluminal coronary angioplasty, or coronary artery bypass graft within the six months prior to enrolment.
- •6. Congestive heart failure (New York Heart Association [NYHA]13 class III or IV).
- •7. Patients with known liver disease or elevated serum transaminase (aspartate aminotransferase [AST] or alanine aminotransferase [ALT]) greater than twice the upper limit of normal (ULN) (Comment: Hepatitis B-virus surface antigen (HBsAg) carrier status or positive antibodies to hepatitis C virus (HCV) per se is not defined as an exclusion criterion if transaminases are within the normal range).
- •8. Severe metabolic acidosis (bicarbonate <18 mEq/L [18 mmol/L]).
- •9. Tertiary or poorly controlled secondary hyperparathyroidism defined as intact parathyroid hormone (PTH) = 10 times the ULN.
- •10. Severe endogenous depression or schizophrenia.
- •11. Current malignant disease.
- •12. Current systemic infection or inflammatory disease.
- •13. Known positive test for human immunodeficiency virus (HIV) antibodies.
- •14. Concomitant therapy with immunosuppressive drugs, steroids (oral or intravenous) or androgens.
- •15. Therapy with androgens within the last 3 months prior to enrolment.
- •16. Patients with resistance to Epoetin (more than 300 IU/kg/week).
- •17. Patients who have been treated with Epoetins with a longer half life time (e.g. novel erythropoiesis stimulating protein [NESP], continuous erythropoietin receptor activator [CERA]) within the last 6 months.
- •18. Known hypersensitivity (drug intolerance or allergy) to Epoetin or excipients of the formulation.
- •19. Known presence of antibodies to Epoetin.
- •20. Known or suspected drug abuse or alcohol abuse.
- •21. Participation in a study with investigational drugs within 30 days prior to enrolment.
- •22. Planned travel activities outside the participating countries during the study.
- •Under no circumstances may patients be enrolled into this study more than once.
研究者
相似试验
进行中（未招募）
不适用
Efficacy and Safety of subcutaneous administration of XM01 and Epoetin beta for treatment of anaemia in chronic renal failure patients not yet receiving dialysis. A multinational, multicentre, randomised, controlled, double-blind, parallel group phase II study.EUCTR2005-000140-85-HUBioGeneriX AG150
已完成
4 期
Efficacy and Safety of Subcutaneous Administration of Lyophilized Powder of Alpha-Erythropoietin to Maintains Hemoglobin Concentrations among Hemodialysis PatientsAnemia associated with chronic kidney diseaseHemodialysisLyophilised powderErythropoietinAnemiaTCTR20161214001Phramongkutklao hospital and College of Medicine63
招募中
2 期
The efficacy and safety of subcutaneous injection of bortezomib combined with doxorubicin and dexamethasone for untreated multiple myeloma patients.multiple myelomaJPRN-UMIN000007803ational Hospital Organization Disaster Medical Center35
进行中（未招募）
1 期
Safety and efficacy of subcutaneous (SC) administration of Clinimix N9G15E in elderly patients at risk for malnutrition, at a dose of 1 liter infused over 12 hours for 7 to 10 consecutive days. A prospective, multicentre, randomized, open-label, non-inferiority, controlled phase III B trial carried out in parallel groups: subcutaneous versus peripheral intravenous administration.EUCTR2007-006153-31-FRBaxter R and D Europe SCR120
招募中
3 期
Safety, efficacy and exposure of subcutaneously administered NNC0365-3769 (Mim8) prophylaxis in children with haemophilia A with or without FVIII inhibitorsblood clothing disorderHaemophilia A10064477NL-OMON51874ovo Nordisk4